Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma

Dhule, Santosh S.; Penfornis, Patrice; Frazier, Trivia; Walker, Ryan W.; Feldman, Joshua; Tan, Grace; He, Jibao; Alb, Alina M.; John, Vijay T.; Pochampally, Radhika

doi:10.1016/j.nano.2011.07.011

Cited by 267 publications

(147 citation statements)

References 48 publications

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…Passive loading often leads to undesirable membrane incorporation, lowering liposome stability, and is much less efficient than active loading. For example, the drug:lipid ratios achieved through the unique approach described here ranged from 0.4 to 0.6, which is more than 1,000-fold higher than the drug:lipid ratios commonly achieved through passive loading (65)(66)(67)(68)(69)72).…”

Section: Discussionmentioning

confidence: 73%

See 1 more Smart Citation

Remote loading of preencapsulated drugs into stealth liposomes

Sur

Fries

Kinzler

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

119

View full text Add to dashboard Cite

Loading drugs into carriers such as liposomes can increase the therapeutic ratio by reducing drug concentrations in normal tissues and raising their concentrations in tumors. Although this strategy has proven advantageous in certain circumstances, many drugs are highly hydrophobic and nonionizable and cannot be loaded into liposomes through conventional means. We hypothesized that such drugs could be actively loaded into liposomes by encapsulating them into specially designed cyclodextrins. To test this hypothesis, two hydrophobic drugs that had failed phase II clinical trials because of excess toxicity at deliverable doses were evaluated. In both cases, the drugs could be remotely loaded into liposomes after their encapsulation (preloading) into cyclodextrins and administered to mice at higher doses and with greater efficacy than possible with the free drugs.T here is currently wide interest in the development of nanoparticles for drug delivery (1-7). This area of research is particularly relevant to cancer drugs, wherein the therapeutic ratio (dose required for effectiveness to dose causing toxicity) is often low. Nanoparticles carrying drugs can increase this therapeutic ratio over that achieved with the free drug through several mechanisms. In particular, drugs delivered by nanoparticles are thought to selectively enhance the concentration of the drugs in tumors as a result of the enhanced permeability and retention (EPR) effect (8-18). The enhanced permeability results from a leaky tumor vascular system, whereas the enhanced retention results from the disorganized lymphatic system that is characteristic of malignant tumors.Much current work in this field is devoted to designing novel materials for nanoparticle generation. This new generation of nanoparticles can carry drugs-particularly those that are insoluble in aqueous medium-that are difficult to incorporate into conventional nanoparticles such as liposomes. However, the older generation of nanoparticles has a major practical advantage in that they have been extensively tested in humans and approved by regulatory agencies such as the Food and Drug Administration in the United States and the European Medicines Agency in Europe. Unfortunately, many drugs cannot be easily or effectively loaded into liposomes, thereby compromising their general use.In general, liposomal drug loading is achieved by either passive or active methods (9,(19)(20)(21)(22). Passive loading involves dissolution of dried lipid films in aqueous solutions containing the drug of interest. This approach can only be used for water-soluble drugs, and the efficiency of loading is often low. In contrast, active loading can be extremely efficient, resulting in high intraliposomal concentrations and minimal wastage of precious chemotherapeutic agents (9,23,24). In active loading, drug internalization into preformed liposomes is typically driven by a transmembrane pH gradient. The pH outside the liposome allows some of the drug to exist in an unionized form, able to migrate across the lipid bi...

show abstract

Section: Discussionmentioning

confidence: 73%

“…Previous attempts to combine cyclodextrin inclusion complexes with liposomes were limited to passive loading of insoluble drugs (65)(66)(67)(68)(69)(70)(71) or active loading of soluble drugs (72). Passive loading often leads to undesirable membrane incorporation, lowering liposome stability, and is much less efficient than active loading.…”

Section: Discussionmentioning

confidence: 99%

Remote loading of preencapsulated drugs into stealth liposomes

Sur

Fries

Kinzler

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

119

View full text Add to dashboard Cite

show abstract

“…The combinatorial liposomes were prepared by thin film evaporation method as per the description by Dhule et al [19], Banerjee et al [20], Gong et al [21] and Pulford et al [22] with suitable modifications. Active extrusion method was utilized where drugs are suspended with phospholipids in aqueous solution [6].…”

Section: Methodsmentioning

confidence: 99%

Impediment of selenite-induced cataract in rats by combinatorial drug laden liposomal preparation

Huang

Muhemaitia

2018

Libyan Journal of Medicine

View full text Add to dashboard Cite

Cataract is the leading cause of blindness globally with surgery being the only form of treatment. But cataract surgery is accompanied by complications, chiefly intra-ocular infections. Hence, preventive nanoformulations may be extremely beneficial. In the present study, novel chitosan-coated liposomal formulations encapsulating a combination of drugs, lanosterol and hesperetin were prepared and characterized. The combinatorial liposomes were prepared by thin film evaporation active extrusion method. The characterization of liposomes was done by transmission electron microscopy, zeta potential, encapsulation efficiency, stability, cytotoxicity and in vitro release studies. The main difference between the chitosan-coated and uncoated combinatorial liposomes is the release of drugs as indicated by the in vitro release studies. The slow and sustained release of the drugs from chitosan-coated ones as against the burst release from uncoated indicates an increased retention time for combinatorial drugs in cornea. This leads to a delay in progression of cataract as seen from in vivo studies. Cytotoxicity studies indicate no cell toxicity of the coating of chitosan or the combination of drugs. Stability studies indicate that there were almost no changes in size, zeta potential and polydispersity index values of the combinatorial liposomes upon storage at room temperature for 60 days. Another important study is the estimation of antioxidant defense system. The estimated values of glutathione reductase, malondialdehyde and chief antioxidant enzymes point toward an upregulation of antioxidant defense system. From the results, it may be concluded that novel chitosan-coated combinatorial liposomes are effective in delaying or preventing of cataract.

show abstract

“…Curcumin can inhibit the proliferation of a series of osteosarcoma cells, including MG63 [13][14][15], U2OS [15][16][17][18][19][20], MNNG/HOS [21], and KHOS [22], according to literature reports. However, a question remained to answer is whether the curcumin is valid for the treatment of highly metastatic human osteosarcoma.…”

Section: Introductionmentioning

confidence: 99%

Curcumin-encapsulated polymeric nanoparticles for metastatic osteosarcoma cells treatment

et al. 2017

View full text Add to dashboard Cite

Osteosarcoma is a high-class malignant bone cancer with a less than 20% five-year survival rate due to its early metastasis potential. There is an urgent need to develop a versatile and innoxious drug to treat metastatic osteosarcoma. Curcumin (Cur) has shown its potential for the treatment of many cancers; however, the clinical implication of native curcumin is severely hindered by its intrinsic property. In this study, a mixed system of monomethoxy (polyethylene glycol)-poly(d, l-lactide-co-glycolide)/poly(ε-caprolactone) (mPEG-PLGA/PCL) was used to build a formulation of curcuminencapsulated nanoparticles (Cur-NPs), which significantly improved the solubility, stability and cellular uptake of curcumin. Moreover, the Cur-NPs were superior to free curcumin in the matter of inhibition on the proliferation, migration and invasion of osteosarcoma 143B cells. It was found that both free curcumin and Cur-NPs could decrease the expressions of c-Myc and MMP7 in the level of mRNA and protein, which explained why free curcumin and Cur-NPs could inhibit the proliferation and invasion of metastatic osteosarcoma 143B cells. The Cur-NPs provided a promising strategy for metastatic osteosarcoma treatment.

show abstract

Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma

Cited by 267 publications

References 48 publications

Remote loading of preencapsulated drugs into stealth liposomes

Remote loading of preencapsulated drugs into stealth liposomes

Impediment of selenite-induced cataract in rats by combinatorial drug laden liposomal preparation

Curcumin-encapsulated polymeric nanoparticles for metastatic osteosarcoma cells treatment

Contact Info

Product

Resources

About